---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026709"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T19:48:42.143818+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novavax reports Q4 2022 revenue $357M, net loss $182M; raises going concern doubt

## Summary
- Q4 revenue $357M (+61% YoY), full year $1.9B (+73% YoY); net loss Q4 $182M, full year $658M.
- Cash $1.3B as of Dec 31, 2022; raised $250M in convertible notes and equity in Dec 2022.
- Appointed John C. Jacobs as President and CEO; raised going concern doubt about ability to continue through next year.
- Updated US government agreement for up to 1.5M additional doses in 2023; initiated Phase 2 trial for COVID-19-Influenza combo vaccine.
- Expanded Nuvaxovid label in adult booster and adolescent primary series.

## SEC filing metadata
- accession: 0001104659-23-026709
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/tm237994d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026709
- JSON: https://secwatch.observer/filing/0001104659-23-026709.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026709.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported full year 2022 results: revenue $1.9 billion.
  - Period: full year 2022
  - Revenue: $1.9 billion
  - Result: reported results
  source text: Total revenue for the full year 2022 was $1.9 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm
- Earnings Releases
  NOVAVAX INC reported fourth quarter 2022 results: revenue $357 million.
  - Period: fourth quarter 2022
  - Revenue: $357 million
  - Result: reported results
  source text: Total revenue for the fourth quarter 2022 was $357 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.